Priority Review Voucher Fee Decreases For FY 2021 May Reflect US FDA Personnel Changes
In part because assessment costs plummeted in FY 2019, the FY 2021 fee to redeem a priority review voucher will be 37% less than the previous year.
You may also be interested in...
Both sides want enhancements to deal with growth in cell and gene therapy, as well as work on regulatory decision tools and finance issues.
US incentive program would gain only four more years, despite calls for a permanent extension.
The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.